Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 100

1.

Selective BCL-2 inhibition by ABT-199 causes on-target cell death in acute myeloid leukemia.

Pan R, Hogdal LJ, Benito JM, Bucci D, Han L, Borthakur G, Cortes J, DeAngelo DJ, Debose L, Mu H, Döhner H, Gaidzik VI, Galinsky I, Golfman LS, Haferlach T, Harutyunyan KG, Hu J, Leverson JD, Marcucci G, Müschen M, Newman R, Park E, Ruvolo PP, Ruvolo V, Ryan J, Schindela S, Zweidler-McKay P, Stone RM, Kantarjian H, Andreeff M, Konopleva M, Letai AG.

Cancer Discov. 2014 Mar;4(3):362-75. doi: 10.1158/2159-8290.CD-13-0609. Epub 2013 Dec 17.

PMID:
24346116
[PubMed - in process]
2.

Identification of expression signatures predictive of sensitivity to the Bcl-2 family member inhibitor ABT-263 in small cell lung carcinoma and leukemia/lymphoma cell lines.

Tahir SK, Wass J, Joseph MK, Devanarayan V, Hessler P, Zhang H, Elmore SW, Kroeger PE, Tse C, Rosenberg SH, Anderson MG.

Mol Cancer Ther. 2010 Mar;9(3):545-57. doi: 10.1158/1535-7163.MCT-09-0651. Epub 2010 Feb 23.

PMID:
20179162
[PubMed - indexed for MEDLINE]
Free Article
3.

Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A.

J Clin Invest. 2007 Jan;117(1):112-21.

PMID:
17200714
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.

Konopleva M, Milella M, Ruvolo P, Watts JC, Ricciardi MR, Korchin B, McQueen T, Bornmann W, Tsao T, Bergamo P, Mak DH, Chen W, McCubrey J, Tafuri A, Andreeff M.

Leukemia. 2012 Apr;26(4):778-87. doi: 10.1038/leu.2011.287. Epub 2011 Nov 8.

PMID:
22064351
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Selective bcl-2 inhibition to treat chronic lymphocytic leukemia and non-hodgkin lymphoma.

Ng SY, Davids MS.

Clin Adv Hematol Oncol. 2014 Apr;12(4):224-9.

PMID:
25003352
[PubMed - in process]
6.

Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo.

Kang MH, Kang YH, Szymanska B, Wilczynska-Kalak U, Sheard MA, Harned TM, Lock RB, Reynolds CP.

Blood. 2007 Sep 15;110(6):2057-66. Epub 2007 May 29.

PMID:
17536015
[PubMed - indexed for MEDLINE]
Free Article
7.

BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

Bogenberger JM, Kornblau SM, Pierceall WE, Lena R, Chow D, Shi CX, Mantei J, Ahmann G, Gonzales IM, Choudhary A, Valdez R, Camoriano J, Fauble V, Tiedemann RE, Qiu YH, Coombes KR, Cardone M, Braggio E, Yin H, Azorsa DO, Mesa RA, Stewart AK, Tibes R.

Leukemia. 2014 Jan 23. doi: 10.1038/leu.2014.44. [Epub ahead of print]

PMID:
24451410
[PubMed - as supplied by publisher]
8.

Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199.

Khaw SL, Mérino D, Anderson MA, Glaser SP, Bouillet P, Roberts AW, Huang DC.

Leukemia. 2014 Jun;28(6):1207-15. doi: 10.1038/leu.2014.1. Epub 2014 Jan 9.

PMID:
24402163
[PubMed - in process]
9.

Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.

Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ, Cohen GM.

Blood. 2009 Apr 30;113(18):4403-13. doi: 10.1182/blood-2008-08-173310. Epub 2008 Nov 13.

PMID:
19008458
[PubMed - indexed for MEDLINE]
Free Article
10.

BH3 mimetic ABT-737 neutralizes resistance to FLT3 inhibitor treatment mediated by FLT3-independent expression of BCL2 in primary AML blasts.

Kohl TM, Hellinger C, Ahmed F, Buske C, Hiddemann W, Bohlander SK, Spiekermann K.

Leukemia. 2007 Aug;21(8):1763-72. Epub 2007 Jun 7.

PMID:
17554384
[PubMed - indexed for MEDLINE]
11.

Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation.

Kang MH, Wan Z, Kang YH, Sposto R, Reynolds CP.

J Natl Cancer Inst. 2008 Apr 16;100(8):580-95. doi: 10.1093/jnci/djn076. Epub 2008 Apr 8.

PMID:
18398104
[PubMed - indexed for MEDLINE]
Free Article
12.

Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.

Rahmani M, Aust MM, Attkisson E, Williams DC Jr, Ferreira-Gonzalez A, Grant S.

Cancer Res. 2013 Feb 15;73(4):1340-51. doi: 10.1158/0008-5472.CAN-12-1365. Epub 2012 Dec 12.

PMID:
23243017
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

The BH3-only mimetic ABT-737 synergizes the antineoplastic activity of proteasome inhibitors in lymphoid malignancies.

Paoluzzi L, Gonen M, Bhagat G, Furman RR, Gardner JR, Scotto L, Gueorguiev VD, Heaney ML, Manova K, O'Connor OA.

Blood. 2008 Oct 1;112(7):2906-16. doi: 10.1182/blood-2007-12-130781. Epub 2008 Jun 30.

PMID:
18591385
[PubMed - indexed for MEDLINE]
Free Article
14.

CELL AND MOLECULAR DETERMINANTS OF IN VIVO EFFICACY OF THE BH3 MIMETIC ABT-263 AGAINST PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA XENOGRAFTS.

Suryani S, Carol H, Ni Chonghaile T, Frismantas V, Sarmah C, High L, Bornhauser B, Cowley MJ, Szymanska B, Evans K, Boehm I, Tonna E, Jones L, Moradi Manesh D, Kurmasheva RT, Billups CA, Kaplan W, Letai A, Bourquin JP, Houghton P, Smith MA, Lock RB.

Clin Cancer Res. 2014 Jul 10. pii: clincanres.0259.2014. [Epub ahead of print]

PMID:
25013123
[PubMed - as supplied by publisher]
15.

γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.

Séveno C, Loussouarn D, Bréchet S, Campone M, Juin P, Barillé-Nion S.

Breast Cancer Res. 2012 Jun 15;14(3):R96.

PMID:
22703841
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

BCL-2 dependence and ABT-737 sensitivity in acute lymphoblastic leukemia.

Del Gaizo Moore V, Schlis KD, Sallan SE, Armstrong SA, Letai A.

Blood. 2008 Feb 15;111(4):2300-9. Epub 2007 Dec 4.

PMID:
18056841
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.

Simonin K, N'Diaye M, Lheureux S, Loussouarn C, Dutoit S, Briand M, Giffard F, Brotin E, Blanc-Fournier C, Poulain L.

Apoptosis. 2013 Apr;18(4):492-508. doi: 10.1007/s10495-012-0799-x.

PMID:
23344663
[PubMed - indexed for MEDLINE]
18.

Initial testing (stage 1) of the BH3 mimetic ABT-263 by the pediatric preclinical testing program.

Lock R, Carol H, Houghton PJ, Morton CL, Kolb EA, Gorlick R, Reynolds CP, Maris JM, Keir ST, Wu J, Smith MA.

Pediatr Blood Cancer. 2008 Jun;50(6):1181-9.

PMID:
18085673
[PubMed - indexed for MEDLINE]
19.

Maturation Stage of T-cell Acute Lymphoblastic Leukemia Determines BCL-2 versus BCL-XL Dependence and Sensitivity to ABT-199.

Ni Chonghaile T, Roderick JE, Glenfield C, Ryan J, Sallan SE, Silverman LB, Loh ML, Hunger SP, Wood B, DeAngelo DJ, Stone R, Harris M, Gutierrez A, Kelliher MA, Letai A.

Cancer Discov. 2014 Jul 3. pii: CD-14-0353. [Epub ahead of print]

PMID:
24994123
[PubMed - as supplied by publisher]
20.

ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.

Russo M, Spagnuolo C, Volpe S, Tedesco I, Bilotto S, Russo GL.

Biochem Pharmacol. 2013 Apr 1;85(7):927-36. doi: 10.1016/j.bcp.2013.01.011. Epub 2013 Jan 24.

PMID:
23353698
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk